A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

被引：0
|
作者：
Oh, Stephen [1 ]
Kiladjian, Jean-Jacques [2 ]
Palandri, Francesca [3 ]
Gotlib, Jason [4 ]
Mohan, Sanjay [5 ]
Ali, Haris [6 ]
Asatiani, Ekatherine [7 ]
Seguy, Francis [7 ]
Zhou, Feng [8 ]
Verstovsek, Srdan [9 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Univ Paris, INSERM, Hop St Louis, AP HP, Paris, France
[3] Azienda Osped Univ Bologna, IRCCS Ist Ricovero & Cura Carattere Sci, Policlin S Orsola Malpighi, Bologna, Italy
[4] Stanford Canc Inst, Stanford, CA USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] City Hope Med Ctr, Duarte, CA USA
[7] Incyte Biosci Int Sarl, Morges, Switzerland
[8] Incyte Corp, Wilmington, DE USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH2021-PO
引用
收藏
页码：111 / 112
页数：2
相关论文
共 50 条
  • [31] Bromodomain and Extra-terminal (BET) Inhibitor INCB057643 in Patients With Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
    Vachhani, Pankit
    Vannucchi, Alessandro M.
    Hunter, Anthony M.
    McMahon, Brandon
    Tantravahi, Srinivas K.
    Iurlo, Alessandra
    Xicoy, Blanca
    Palandri, Francesca
    Searle, Emma
    Reeves, Brandi
    Bose, Prithviraj
    Diaz, Rosa Ayala
    Halpern, Anna B.
    Chen, Xuejun
    Burke, Lea
    Zhou, Feng
    Zheng, Fred
    Watts, Justin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S415 - S415
  • [32] Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis
    Gill, Harinder
    Au, Lester
    Leung, Garret Man Kit
    Tsai, Dorothy
    Yim, Rita
    Chin, Lynn
    Li, Vivian
    Lee, Paul
    Leung, Rock Yuk Yan
    Lee, Elaine
    Rienhoff, Hugh Young, Jr.
    Kwong, Yok Lam
    BLOOD, 2023, 142
  • [33] Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis
    Mascarenhas, John O.
    Talpaz, Moshe
    Gupta, Vikas
    Foltz, Lynda M.
    Savona, Michael R.
    Paquette, Ron
    Turner, Robert
    Coughlin, Paul
    Winton, Elliott
    Hunter, Deborah
    Assad, Albert
    Clark, Jason
    O'Neill, Peter
    Hoffman, Ronald
    Verstovsek, Srdan
    BLOOD, 2014, 124 (21)
  • [34] Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
    Francisco Cervantes
    David M. Ross
    Atanas Radinoff
    Francesca Palandri
    Alexandr Myasnikov
    Alessandro M. Vannucchi
    Pierre Zachee
    Heinz Gisslinger
    Norio Komatsu
    Lynda Foltz
    Francesco Mannelli
    Francesco Passamonti
    Geralyn Gilotti
    Islam Sadek
    Ranjan Tiwari
    Evren Zor
    Haifa Kathrin Al-Ali
    Leukemia, 2021, 35 : 3626 - 3626
  • [35] Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma
    Gibney, Geoffrey Thomas
    Hamid, Omid
    Gangadhar, Tara C.
    Lutzky, Jose
    Olszanski, Anthony J.
    Gajewski, Thomas
    Chmlelowski, Bartosz
    Boasberg, Peter D.
    Zhao, Yufan
    Newton, Robert Charles
    Scherle, Peggy A.
    Bowman, Jill
    Maleski, Janet
    Leopold, Lance
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES TREATED WITH A PI3K DELTA INHIBITOR (INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1 INHIBITOR (INCB039110)
    Phillips, T.
    Forero-Torres, A.
    Sher, T.
    Diefenbach, C.
    Talpaz, M.
    Scherle, P.
    Schaub, R.
    Zhou, L.
    Pulini, J.
    Leopold, L.
    Spear, M.
    Barr, P.
    HAEMATOLOGICA, 2015, 100 : 110 - 110
  • [37] Phase 1/2 study of INCB054329, a bromodomain and extraterminal (BET) protein inhibitor, in patients (pts) with advanced malignancies
    Falchook, Gerald
    Talpaz, Moshe
    Mita, Monica
    Szmulewitz, Russ
    Piha-Paul, Sarina
    Harb, Wael
    Morgensztern, Daniel
    Kaplan, Jason
    Munster, Pamela
    Cornell, Robert F.
    Zheng, Fred
    Yeleswaram, Swamy
    Zhou, Gongfu
    Cassaday, Ryan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [38] Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study
    Watts, Justin M.
    Vannucchi, Alessandro M.
    Hunter, Anthony
    McMahon, Brandon
    Tantravahi, Srinivas Kiran
    Iurlo, Alessandra
    Xicoy, Blanca
    Palandri, Francesca
    Searle, Emma
    Reeves, Brandi
    Bose, Prithviraj
    Diaz, Rosa Ayala
    Halpern, Anna B.
    Chen, Xuejun
    Burke, Lea Micaletti
    Zhou, Feng
    Zheng, Fred
    Vachhani, Pankit
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies
    Zeidan, Amer M.
    Cook, Rachel J.
    Bordoni, Rodolfo
    Berenson, James R.
    Edenfield, William J.
    Mohan, Sanjay
    Zhou, Gongfu
    Asatiani, Ekaterine
    Srinivas, Nithya
    Savona, Michael R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 523 - 534
  • [40] Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study
    Gupta, Vikas
    Wolleschak, Denise
    Hasselbalch, Hans
    Vannucchi, Alessandro Maria
    Koschmieder, Steffen
    Cervantes, Francisco
    Li, Yang
    Dong, Tuochuan
    Wroclawska, Monika
    Bharathy, Savita
    Harrison, Claire
    BLOOD ADVANCES, 2020, 4 (13) : 3063 - 3071
12345